Melanoma: 5-Year Survival with Ipi & Nivo Therapy
Melanoma Breakthrough: Five-Year Data Shows High Survival Rates with Novel Immunotherapy Approach Groundbreaking five-year follow-up data reveals remarkably positive outcomes for patients with high-risk stage III melanoma treated with a combination of immunotherapy drugs, followed by surgery and additional therapy tailored to their response. The findings, stemming from the PRADO extension cohort of the OpACIN-neo … Read more